Sepracor Inc. (SEPR) - Financial and Strategic Analysis Review by GlobalData

VIEWS: 39 PAGES: 32

More Info
									                Sepracor Inc. (SEPR) - Financial and Strategic Analysis Review

       Reference Code: GDME17966FSA                                                                                     Publication Date: JUL 2010

       84 Waterford Drive                       Phone              +1 508 4816700                       Revenue            1,292.3 (million USD)
       Marlborough, MA                          Fax                +1 508 3577499                       Net Profit         NA
       01752                                    Website            www.sepracor.com                     Employees          2,400
       United States                            Exchange           SEPR [NASDAQ]                        Industry           Medical Equipment

      Company Overview
       Sepracor Inc. (Sepracor) is a research oriented pharmaceutical company that is principally engaged in the research,
       development, sales and marketing of unique pharmaceutical products used in the treatment and prevention of human disease.
       The company develops products in two therapeutic areas, respiratory diseases and central nervous system (CNS) disorders. Its
       existing product portfolio and the pipeline candidates are targeted at treating patients of epilepsy, anxiety, depression, asthma,
       pain, allergic rhinitis and chronic obstructive pulmonary disease. Sepracor’s key customers include medical institutions, hospitals
       and general public. It has its presence across the US and Canada.

      Key Executives                                                                SWOT Analysis
                    Name                                   Title                    Sepracor Inc., SWOT Analysis
      Saburo Hamanaka                      Chairman                                 Strengths                   Weaknesses

      Robert F. Scumaci                    Executive Vice President
                                                                                    Efficient Use of Resources          Patent Infringement Claims
      Andrew I. Koven                      Executive Vice President
      Mark Iwicki                          Chief Operating Officer                  Focused Research and                Limited Liquidity Position
                                                                                    Development
      Nobuhiko Tamura                      Chief Scientific Officer
      Source: Annual Report, Company Website, Primary and Secondary Research
      GlobalData
                                                                                    Opportunities                       Threats
      Share Data
       Sepracor Inc.                                                                Acquisition of Oryx                 Increased Pricing Control
       Share Price (USD) as on 20-Oct-2009                                23.0      Pharmaceuticals Inc.

                                                                          4.47                                          Tightening of the FDA’s
       EPS (USD)
                                                                                    Potential Market                    Regulatory Oversight
       Market Cap (million USD)                                          2,551

       Enterprise Value (million USD)                                    2,469

       Shares Outstanding (million)                                        111      Source: Annual Report, Company Website, Primary and Secondary Research
       Source: Annual Report, Company Website, Primary and Secondary Research       GlobalData
       GlobalData

      Financial Performance                                            
								
To top